SCHEDULE 13G/A: Insider Eric Easom Discloses 6.2% Stake in AN2 Therapeutics
Beneficial Ownership Report
Eric Easom, a U.S. citizen, has reported beneficial ownership of 6.2% of AN2 Therapeutics, Inc.'s common stock as of December 31, 2024, through a Schedule 13G Amendment No. 1 filing.
Summary
- Eric Easom, the Reporting Person, beneficially owns 1,893,132 shares of AN2 Therapeutics, Inc. Common Stock.
- This ownership represents 6.2% of the company's outstanding Common Stock.
- The calculation is based on 29,878,890 shares of Common Stock outstanding as of November 6, 2024, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed on November 13, 2024.
- The 1,893,132 shares consist of: 2,130 shares held directly by Mr. Easom, 1,259,882 shares held by various family trusts where Mr. Easom serves as trustee, 24,750 shares underlying restricted stock units vesting within 60 days of December 31, 2024, and 606,370 shares underlying stock options that are vested or will vest within 60 days of December 31, 2024.
- Mr. Easom holds sole voting and sole dispositive power over all 1,893,132 beneficially owned shares.
Sentiment
Score: 5
Explanation: The filing is a standard beneficial ownership disclosure, providing factual information without inherent positive or negative performance implications for the company.
Positives
- A significant beneficial ownership stake by an insider like Eric Easom (6.2%) can align management's interests with those of shareholders, potentially indicating confidence in the company's future.
Future Outlook
This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future outlook.
Industry Context
This filing is a standard regulatory disclosure of an individual's significant ownership stake in a publicly traded company. It does not provide information on broader industry trends or competitive landscape.
Related Party Transactions
- A significant portion of the beneficially owned shares (1,259,882 shares) are held by various family trusts over which Eric Easom serves as trustee.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant insider's ownership stake, which can influence investor confidence and perception of alignment between management and shareholder interests.
Key Dates
| Date | Description |
|---|---|
| 2024-11-06 | Date as of which 29,878,890 shares of Common Stock were outstanding, used for percentage calculation. |
| 2024-11-13 | Date AN2 Therapeutics, Inc. filed its Quarterly Report on Form 10-Q with the SEC, disclosing shares outstanding. |
| 2024-12-31 | Date of event which requires the filing of this Schedule 13G statement. |
| 2025-02-13 | Date the Schedule 13G statement was signed by Eric Easom. |
Keywords
AN2 Therapeutics, Eric Easom, Schedule 13G, beneficial ownership, common stock, insider ownership, SEC filing, equity stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.